retatrutide type 2 diabetes Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial ADA 2026: Retatrutide Revolution

Usage and visibility of GLP-1s have been increasing, especially among younger generations

Understanding why you might not be losing weight on semaglutide can help identify what needs adjustment

Retatrutide can help address these issues

Critically, there is no substantial clinical evidence demonstrating that over-the-counter supplements can replicate the pharmacological effects of prescription GLP-1 receptor agonists

Cardiovascular exercise plays a supporting role

Wegovy and Zepbound are FDA-approved for weight management regardless of diabetes status, but many insurance plans have stricter prior authorization requirements for weight-loss indications than for diabetes